Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Luxturna concentrate and solvent for solution for injection {equilateral_black_triangle}

Active Ingredient:
voretigene neparvovec
Company:  
Novartis Pharmaceuticals UK Ltd See contact details
ATC code: 
S01XA27
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Audio/Video HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Luxturna (voretigene neparvovec) - Patient Alert card - for Patients

Patient card to track treatment and provide useful contact details
{pdf_link}

Luxturna (voretigene neparvovec) - Patient information leaflet A4 - for Patients

Patient information leaflet size A4

Update to Section 4 (Possible side effects) of the PIL and Date of Revision

{pdf_link}

Luxturna (voretigene neparvovec) - Pharmacy training material - for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Pharmacy manual for dose preparation of Luxturna
{pdf_link}

Luxturna (voretigene neparvovec) - Surgical training material - for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Surgical manual for the administration of Luxturna

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Novartis Pharmaceuticals UK Ltd
Company image
Address
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Telephone
+44 (0)1276 692 255
Medical Information Direct Line
+44 (0)1276 698 370
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)845 741 9442
E-mail
[email protected]